The role of bisphosphonates in breast cancer
The role of bisphosphonates in breast cancer
复制标题
DOI：
10.1016/j.breast.2004.09.004
复制
发表时间：
2004-12-01
期刊：
影响因子：
3.9
通讯作者：
Coleman, RE
中科院分区：
文献类型：
--
作者：
Coleman, RE
乳腺癌骨转移患者发生骨骼并发症的风险很高。双膦酸盐是肿瘤诱导的骨吸收的有效抑制剂，显著降低了这些患者的骨骼并发症的风险。几种双膦酸盐已被研究用于治疗乳腺癌患者的骨转移，包括氯屈膦酸盐、帕米磷酸钠、伊班磷酸钠和唑来膦酸。在这些药物中，基于保守的终点，静脉注射帕米磷酸钠和唑来膦酸显示出最大的临床益处。唑来膦酸是唯一可以与另一种活性双膦酸盐进行比较的药物，与帕米磷酸钠相比，它已被证明可显著降低骨骼并发症的风险。基于这些结果，唑来膦酸迅速成为治疗乳腺癌骨转移患者的新的国际标准。(C)2004爱思唯尔有限公司。保留所有权利。
Patients with bone metastases from breast cancer are at high risk for debilitating skeletal complications. Bisphosphonates are effective inhibitors of tumour-induced bone resorption and significantly reduce the risk of skeletal complications in these patients. Several bisphosphonates have been investigated for the treatment of bone metastases in patients with breast cancer, including clodronate, pamidronate, ibandronate, and zoledronic acid. Among these agents, intravenous pamidronate and zoledronic acid have demonstrated the greatest clinical benefit based on conservative endpoints. Zoledronic acid is the only agent to be compared with another active bisphosphonate and has been shown to significantly reduce the risk of skeletal complications compared with pamidronate. On the basis of these results, zoledronic acid has rapidly become the new international standard of care for patients with bone metastases from breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.